Last reviewed · How we verify
vunakizumab and recaticimab.
Vunakizumab and recaticimab are monoclonal antibodies that target inflammatory cytokines to modulate immune responses in inflammatory and autoimmune conditions.
Vunakizumab and recaticimab are monoclonal antibodies that target inflammatory cytokines to modulate immune responses in inflammatory and autoimmune conditions. Used for Inflammatory bowel disease, Psoriasis, Rheumatoid arthritis.
At a glance
| Generic name | vunakizumab and recaticimab. |
|---|---|
| Sponsor | Xiangya Hospital of Central South University |
| Drug class | Monoclonal antibody (anti-cytokine) |
| Target | IL-12/IL-23 p40 subunit (vunakizumab); TNF-α (recaticimab) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rheumatology |
| Phase | FDA-approved |
Mechanism of action
Vunakizumab is an anti-IL-12/IL-23 monoclonal antibody that blocks the p40 subunit shared by both IL-12 and IL-23, reducing Th1 and Th17 cell differentiation. Recaticimab is an anti-TNF-α monoclonal antibody that inhibits tumor necrosis factor-alpha signaling. Together or individually, these agents suppress pro-inflammatory pathways implicated in autoimmune and inflammatory diseases.
Approved indications
- Inflammatory bowel disease
- Psoriasis
- Rheumatoid arthritis
Common side effects
- Infection (upper respiratory, urinary tract)
- Injection site reactions
- Headache
- Nasopharyngitis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: